Identified ACT as MOH-recommended antimalarial
|
No
|
37% (32)
|
1 (reference)
|
1 (reference)
|
1 (reference)
|
Yes
|
63% (55)
|
3.0 (1.21–7.47; 0.018)**
|
2.34 (0.93–5.88; 0.070)*
|
2.36 (0.92–6.03; 0.073)*
|
Recommended ACT to adults
|
No
|
45% (39)
|
–
|
1 (reference)
|
1 (reference)
|
Yes
|
55% (48)
|
–
|
5.37 (2.08–13.87; 0.001)**
|
8.89 (3.11–25.39; < 0.001)**
|
Recommended ACT to children
|
No
|
55% (48)
|
1 (reference)
|
–
|
1 (reference)
|
Yes
|
45% (39)
|
5.37 (2.08–13.87; 0.001)**
|
–
|
3.76 (1.52–9.28; 0.004)**
|
Sold ACTs more than any other antimalarial
|
No
|
59% (51)
|
1 (reference)
|
1 (reference)
|
–
|
Yes
|
41% (36)
|
8.89 (3.11–25.39; < 0.001)**
|
3.76 (1.52–9.28; 0.004)**
|
–
|
Gave Fansidar to a mother requesting it
|
No
|
81% (70)
|
1 (reference)
|
1 (reference)
|
1 (reference)
|
Yes
|
18% (16)
|
0.67 (0.21–2.01; 0.461)
|
0.36 (0.11–1.25; 0.109)*
|
0.94 (0.30–2.94; 0.919)
|